Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 2
2017 6
2018 1
2019 7
2020 4
2021 2
2022 2
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Clinical considerations for the design of PROTACs in cancer.
Nieto-Jiménez C, Morafraile EC, Alonso-Moreno C, Ocaña A. Nieto-Jiménez C, et al. Mol Cancer. 2022 Mar 7;21(1):67. doi: 10.1186/s12943-022-01535-7. Mol Cancer. 2022. PMID: 35249548 Free PMC article. Review.
Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned.
López de Sá A, Díaz-Tejeiro C, Poyatos-Racionero E, Nieto-Jiménez C, Paniagua-Herranz L, Sanvicente A, Calvo E, Pérez-Segura P, Moreno V, Moris F, Ocana A. López de Sá A, et al. Among authors: nieto jimenez c. J Hematol Oncol. 2023 Dec 12;16(1):118. doi: 10.1186/s13045-023-01519-0. J Hematol Oncol. 2023. PMID: 38087293 Free PMC article. Review.
Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer.
Noblejas-López MDM, Gandullo-Sánchez L, Galán-Moya EM, López-Rosa R, Tébar-García D, Nieto-Jiménez C, Gómez-Juárez M, Burgos M, Pandiella A, Ocaña A. Noblejas-López MDM, et al. Among authors: nieto jimenez c. Int J Mol Sci. 2022 May 13;23(10):5476. doi: 10.3390/ijms23105476. Int J Mol Sci. 2022. PMID: 35628286 Free PMC article.
BET inhibitors as novel therapeutic agents in breast cancer.
Ocaña A, Nieto-Jiménez C, Pandiella A. Ocaña A, et al. Among authors: nieto jimenez c. Oncotarget. 2017 Aug 1;8(41):71285-71291. doi: 10.18632/oncotarget.19744. eCollection 2017 Sep 19. Oncotarget. 2017. PMID: 29050361 Free PMC article. Review.
Genomic Mapping of Epidermal Growth Factor Receptor and Mesenchymal-Epithelial Transition-Up-Regulated Tumors Identifies Novel Therapeutic Opportunities.
Paniagua-Herranz L, Doger B, Díaz-Tejeiro C, Sanvicente A, Nieto-Jiménez C, Moreno V, Pérez Segura P, Gyorffy B, Calvo E, Ocana A. Paniagua-Herranz L, et al. Among authors: nieto jimenez c. Cancers (Basel). 2023 Jun 20;15(12):3250. doi: 10.3390/cancers15123250. Cancers (Basel). 2023. PMID: 37370859 Free PMC article.
Guanylation Reactions for the Rational Design of Cancer Therapeutic Agents.
Del Campo-Balguerías A, Parra-Cadenas B, Nieto-Jimenez C, Bravo I, Ripoll C, Poyatos-Racionero E, Gancarski P, Carrillo-Hermosilla F, Alonso-Moreno C, Ocaña A. Del Campo-Balguerías A, et al. Among authors: nieto jimenez c. Int J Mol Sci. 2023 Sep 7;24(18):13820. doi: 10.3390/ijms241813820. Int J Mol Sci. 2023. PMID: 37762123 Free PMC article.
MZ1 co-operates with trastuzumab in HER2 positive breast cancer.
Noblejas-López MDM, Nieto-Jiménez C, Galán-Moya EM, Tebar-García D, Montero JC, Pandiella A, Burgos M, Ocaña A. Noblejas-López MDM, et al. Among authors: nieto jimenez c. J Exp Clin Cancer Res. 2021 Mar 19;40(1):106. doi: 10.1186/s13046-021-01907-9. J Exp Clin Cancer Res. 2021. PMID: 33741018 Free PMC article.
30 results